Bausch + Lomb (NYSE:BLCO) versus XWELL (NASDAQ:XWEL) Head to Head Survey

Bausch + Lomb (NYSE:BLCO) and XWELL (NASDAQ:XWEL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Insider and Institutional Ownership

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 8.7% of XWELL shares are held by institutional investors. 0.8% of Bausch + Lomb shares are held by company insiders. Comparatively, 13.9% of XWELL shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Bausch + Lomb and XWELL”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$4.98 billion	1.26	-$317.00 million	($0.87)	-20.27
XWELL	$33.90 million	0.07	-$16.85 million	($3.37)	-0.12

XWELL has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than XWELL, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Bausch + Lomb and XWELL, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	2	9	4	0	2.13
XWELL	1	0	0	0	1.00

Bausch + Lomb currently has a consensus target price of $17.42, suggesting a potential downside of 1.25%. Given Bausch + Lomb’s stronger consensus rating and higher possible upside, research analysts plainly believe Bausch + Lomb is more favorable than XWELL.

Profitability

This table compares Bausch + Lomb and XWELL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-6.13%	2.42%	1.15%
XWELL	-51.85%	-352.37%	-64.88%

Volatility and Risk

Bausch + Lomb has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, XWELL has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.

Summary

Bausch + Lomb beats XWELL on 10 of the 14 factors compared between the two stocks.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

About XWELL

XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.